<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707417</url>
  </required_header>
  <id_info>
    <org_study_id>212733</org_study_id>
    <nct_id>NCT04707417</nct_id>
  </id_info>
  <brief_title>Home Care in Allogeneic Haematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Impact of Home Care for Recipients of Allogeneic Haematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mixed methods study with focus groups interviews and a prospective observational cohort study&#xD;
      aimed to investigate the impact of advanced home care on transplant specific outcomes and&#xD;
      quality of life in recipients of allogeneic hematopoietic stem cell transplantation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study of advanced home care after allogeneic haematopoietic stem cell transplantation&#xD;
      (allo-HSCT). The main objective is to investigate the impact of home care on transplant&#xD;
      specific variables and quality of life (QoL). The main hypothesis is that home care patients&#xD;
      will home care patients will have significantly better measured QoL than patients receiving&#xD;
      in-hospital care during the first 6 weeks after allo-HSCT. The study will be conducted as&#xD;
      part of routine care at the departement of haematology, Oslo University Hospital.&#xD;
&#xD;
      There are qualitative and quantitative aspects to the study. The qualitative part involves&#xD;
      focus groups interviews with patients that have been treated with allo-HSCT and have recieved&#xD;
      home care and their caregivers.&#xD;
&#xD;
      In the prospective observational cohort study data will be collected to compare patients&#xD;
      receiving home care and patients treated in-hospital (control group). Patients in both groups&#xD;
      wil answer the questionnaire EORTC QLQ-C30 once weekly for 6 weeks. In addition transplant-&#xD;
      and treatment-specific variables will be collected and compares between the groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>GRFS</measure>
    <time_frame>1 year</time_frame>
    <description>GvHD-free, relapse-free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QoL</measure>
    <time_frame>6 weeks</time_frame>
    <description>Quality of Life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GvHD</measure>
    <time_frame>1 year</time_frame>
    <description>Graft versus host disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRM</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>1 year</time_frame>
    <description>Bacteriemia and invasive fungal disease</description>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Stem Cell Transplant Complications</condition>
  <condition>Quality of Life</condition>
  <condition>GVH - Graft Versus Host Reaction</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home care</intervention_name>
    <description>Advanced home care</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients planned for treatment with allogeneic stem cell transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consent competency and written informed consent to participation&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  Understanding and willing to comply with written and oral instructions in Norwegian&#xD;
&#xD;
          -  Planned treatment with allo-HSCT&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Caregiver (age ≥18) present 24 hours a day during the aplastic phase&#xD;
&#xD;
          -  Travelling distance from residence to the hospital must be less than one hour.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not meeting inclusion criteria&#xD;
&#xD;
          -  Uncontrolled infection or other medical condtion unsuitable for out patient care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Haematology, Division of Cancer Medicine, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Anders E. L. Myhre</investigator_full_name>
    <investigator_title>Consultant Haematologist</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

